Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Am J Transplant. 2019 Jan 9;19(5):1305–1314. doi: 10.1111/ajt.15216

Figure 4. Inhibition of PI3Kδ and Akt potentiates the efficacy of rapamycin in suppressing growth of EBV-positive B cell lymphoma lines in vitro.

Figure 4.

Three EBV-positive B cell lymphoma lines, AB5 (A, B), VB5 (C, D), and MF4 (E, F) were cultured over a range of concentrations of rapamycin plus either CAL-101 (A, C, E) or MK-2206 (B, D, F), for 72 hours. Cell survival (A–F, left panels) was measured and expressed as a percentage relative to control. Each experiment was repeated three times. Isobolograms (A–F, center panels) of two-drug combinations demonstrate that all tested concentrations of the two-drug combinations were below the line of additivity, suggesting synergy. Loewe indices (A–F, right panels) were calculated for each cell line (AB5, VB5, MF4) for both drug combinations (rapamycin + CAL-101 and rapamycin + MK-2206) using the MixLow Package for R. The index of 1.00 is shown (horizontal black line). The 95% confidence interval is shown in the dotted lines.